Drinabant

Drinabant

File:Drinabant.svg
File:Drinabant ball-and-stick model.png
Systematic (IUPAC) name
(±)-N-{1-[bis(4-chlorophenyl)methyl]-3-azetidinyl}-N-(3,5-difluorophenyl)methanesulfonamide
Clinical data
Legal status	Development terminated
Identifiers
CAS Number	358970-97-5
ATC code	None
PubChem	CID: 10278470
ChemSpider	8453947
Chemical data
Formula	C23H20Cl2F2N2O2S
Molecular mass	497.385 g/mol
SMILES Fc1cc(cc(F)c1)N(C4CN(C(c2ccc(Cl)cc2)c3ccc(Cl)cc3)C4)S(=O)(=O)C
InChI InChI=1S/C23H20Cl2F2N2O2S/c1-32(30,31)29(21-11-19(26)10-20(27)12-21)22-13-28(14-22)23(15-2-6-17(24)7-3-15)16-4-8-18(25)9-5-16/h2-12,22-23H,13-14H2,1H3 Key:IQQBRKLVEALROM-UHFFFAOYSA-N

Drinabant (INN; AVE-1625) is a drug that acts as a selective CB₁ receptor antagonist, which was under investigation varyingly by Sanofi-Aventis as a treatment for obesity, schizophrenia, Alzheimer's disease, Parkinson's disease, and nicotine dependence. Though initially studied as a potential treatment for a variety of different medical conditions, Sanofi-Aventis eventually narrowed down the therapeutic indications of the compound to just appetite suppression. Drinabant reached phase IIb clinical trials for this purpose in the treatment of obesity but was shortly thereafter discontinued, likely due to the observation of severe psychiatric side effects including anxiety, depression, and thoughts of suicide in patients treated with the now-withdrawn rimonabant, another CB₁ antagonist that was also under development by Sanofi-Aventis.

See also

• Cannabinoid receptor antagonist